Loteprednol etabonate/tobramycin | 863983-05-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Loteprednol etabonate/tobramycin
• 英文别名: (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-ethoxycarbonyloxy-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-17-carboxylate
• CAS: 863983-05-5
• 化学式: C42H68ClN5O16
• 分子量: 934.5
• InChiKey: JOTNXPXOZZACQR-MDJKOFFZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.38
• 重原子数：
  64
• 可旋转键数：
  13
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  367
• 氢给体数：
  11
• 氢受体数：
  21

文献信息

• OPHTHALMIC, OTIC OR NASAL PHARMACEUTICAL COMPOSITION AND THE USE THEREOF
  申请人：Zhang Jing

  公开号：US20100222308A1

  公开（公告）日：2010-09-02

  The invention provides an ophthalmic, otic or nasal pharmaceutical composition, comprising levofloxacin or the pharmaceutical acceptable salts thereof and loteprednol etabonate, wherein the weight ratio of loteprednol etabonate to levofloxacin is 1:0.2-5. The use of ophthalmic, otic or nasal pharmaceutical composition of the invention in preparation of the medication for treatment of conjunctivitis, keratitis, blepharitis, dacrycystitis, hordeolum, corneal ulcer and ocular infection accompanied with ophthalmitis and even inflammation of the surrounding tissues, to prevent increase of bacterial infection risks and the tissue inflammation of the infected area after the ophthalmic surgeries or ocular injuries, to treat or alleviate the bacterial infection in combination with the tissue inflammation of the infected area, or to treat tympanitis, otitis externa and infective rhinitis.